MedTrace Logo

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

NCT01776203 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2015-03-17

No results posted yet for this study

Summary

In this study, the investigators would like to see if giving medroxyprogesterone acetate for 3 weeks after Leuprolide acetate injection will help to decrease this amount of bleeding, decrease the amount of nausea, bloating and cramping and increase patient satisfaction

Conditions

  • Dysfunctional Uterine Bleeding

Interventions

DRUG

Medroxyprogesterone 17-Acetate

MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks

Sponsors & Collaborators

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Malcolm Munro, MD · Kaiser Permanente

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01776203 on ClinicalTrials.gov